Nektar Therapeutics

1. 01

   Behind SPY and its sector fund XLV over 1 year

   1 month: −3.6% (SPY −1.6%, XLV +13.5%). 3 months: −47.4% (SPY −0.4%, XLV +15.5%). 1 year: −31.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: NKTR, SPY and XLV · as of 4 Nov 2026

2. 02

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $38.48 was 28.1% below its 50-day average ($53.50) and 40.8% below its 200-day average ($65.03). It has closed below the 200-day for 32 sessions, since 22 Sep 2026. The 50-day average crossed below the 200-day on 13 Oct 2026, 16 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

3. 03

   Short interest at 20.5% of shares outstanding

   7.0M shares were sold short at the 15 Oct 2026 settlement, 20.5% of the 34.1M shares outstanding; covering them would take 3.5 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   15.2% above its 52-week low

   Closed at $38.48 on 4 Nov 2026: 64.7% below the 52-week high of $109.00 (20 Apr 2026) and 15.2% above the low of $33.40 (30 Jan 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

5. 05

   Light volume: 0.4× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 498.5K shares was 0.4× the average of the 30 sessions before it (1.4M), as the price rose 1.9%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close